New Efficacy Outcome Analysis in APOE4/4 Patient Subpopulation from Two Prior Tramiprosate Phase 3 Studies Supports Late‐Stage Clinical Program for ALZ‐801m
FRAMINGHAM, Mass., October 27, 2015 – Alzheon, Inc., today announced that the company will be presenting a late‐breaking podium session and a poster at the 8th Clinical Trials on Alzheimer’s Disease Congress in Barcelona, Spain, to be held November 5‐7, 2015. The data presented will include a new analysis from two independent Phase 3 studies of tramiprosate in the subgroup of Alzheimer’s disease (AD) patients with the apolipoprotein E 4/4 (APOE4/4) genotype. The efficacy data provides further support for Alzheon’s clinical program for late‐stage development of ALZ‐801, an optimized prodrug of tramiprosate, in the genetically‐defined population of AD patients with the APOE4/4 genotype.
The details for the presentations are as follows:
1. Late Breaking Presentation (LB #5)
Title: “Robust and Sustained Efficacy of Tramiprosate in APOE4/4 Homozygous Patients with Mild and Moderate AD: Combined Data Sets from Two 78‐ week Phase 3 Trials”
Location: Catalunya C
Date: Friday, November 6, 2015
Time: 12:00 pm (Central European Time)
Presenter: Anton P. Porsteinsson, MD, Professor of Psychiatry at the University of Rochester School of Medicine and Dentistry and Director of the Alzheimer’s Disease Care, Research and Education Program at the University of Rochester, Rochester, N.Y.
Authors: Anton P. Porsteinsson, MD; Jeffrey Cummings, MD, Cleveland Clinic; Mija Kipivelto, MD, PhD, Karolinska University Hospital, Stockholm, Sweden; John Hey, PhD, Alzheon, Inc.; Jeremy Y. Yu, MD, PhD, Alzheon, Inc.; Aidan Power, MD, Alzheon, Inc.; Menghis Bairu, MD, Serenus Biotherapeutics, Inc.; Martin Tolar, MD, PhD, Alzheon, Inc.; Susan Abushakra, MD, Alzheon, Inc.
2. Poster Presentation (P1‐24)
Title: “Cognitive and Functional Efficacy of Tramiprosate in APOE4+ Patients with Mild to Moderate Alzheimer’s Disease: Sub‐group Analyses of the Phase 3 North American and European Trials”
Location: Gaudi Mezzanine Level
Date: Thursday, November 5, 2015
Authors: John Hey, PhD, Alzheon, Inc.; Jeremy Y. Yu, MD, PhD, Alzheon, Inc.; Martin Tolar, MD, PhD, Alzheon, Inc.; Menghis Bairu, MD, Serenus Biotherapeutics, Inc.; John Sampalis, PhD, McGill University
About Alzheon
Alzheon, Inc. is committed to developing innovative medicines for patients suffering from Alzheimer’s disease and other neurological and psychiatric disorders. Our lead clinical candidate, ALZ‐801, is a first in‐class, oral inhibitor of amyloid aggregation and neurotoxicity – hallmarks of Alzheimer’s disease. ALZ‐801 is an optimized, novel prodrug that builds on the established safety and efficacy profile of the active compound in clinical trials of more than 2,000 patients. Our mission is to apply our discovery platform and development experience to unlock new classes of therapeutics that make a difference in patients’ lives by directly addressing the underlying pathology of devastating neurodegenerative disorders.
Contact:
In the U.S.
Kathryn Morris, The Yates Network
845‐635‐9828
kathryn@theyatesnetwork.com
In Europe
Mike Sinclair
+44 (0)20 7318 2955
msinclair@halsin.com